- Condition: Multiple Sclerosis
Interventions: Drug: PR Fampridine; Other: Placebo
Sponsors: Biogen Idec; Biogen Idec
Not yet recruiting - verified May 2012 - Condition: Hyperlipidemias
Intervention: Dietary Supplement: rice bran oil
Sponsors: Qazvin University Of Medical Sciences; Qazvin University Of Medical Sciences
Active, not recruiting - verified May 2012 - Condition: Tonsillectomy
Interventions: Drug: Bupivacaine; Drug: normal saline
Sponsors: King Saud University; King Saud University
Not yet recruiting - verified April 2012 - Condition: Extending Molecular Responses With Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia
Intervention: Drug: nilotinib
Sponsors: King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center
Recruiting - verified April 2012 - Condition: Metastatic Pancreas Cancer
Interventions: Drug: 5FU, leucovorin, oxaliplatin; Drug: Gemcitabine
Sponsors: Alberta Health Services; Alberta Health Services
Not yet recruiting - verified April 2012 - Condition: Lupus Nephritis
Intervention: Drug: Tacrolimus vs. Mycophenolate mofetil for Induction Therapy in Lupus Nephritis
Sponsors: Ramathibodi Hospital; Ramathibodi Hospital; King Chulalongkorn Memorial Hospital; Maharaj Nakorn Chiang Mai Hospital; Rajavithi Hospital; Srinagarind Hospital; Siriraj Hospital; Songklanagarind Hospital
Not yet recruiting - verified April 2012 - Conditions: Relapsed or Refractory Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Interventions: Drug: ofatumumab; Drug: ibrutinib
Sponsors: Pharmacyclics; Pharmacyclics; Janssen Research & Development, LLC
Not yet recruiting - verified May 2012 - Condition: Rheumatoid Arthritis
Interventions: Biological: Adalimumab; Drug: Current adalimumab
Sponsors: Abbott; Abbott
Recruiting - verified April 2012 - Conditions: Pain; Opioid Tolerance; Analgesia Tolerance
Interventions: Drug: Dextromethorphan; Drug: Placebo
Sponsors: King Abdullah International Medical Research Center; King Abdullah International Medical Research Center
Recruiting - verified March 2012 - Condition: Fragile X Syndrome
Intervention: Drug: arbaclofen
Sponsors: Seaside Therapeutics, Inc.; Seaside Therapeutics, Inc.
Enrolling by invitation - verified March 2012 - Condition: Disorders of Gallbladder, Biliary Tract and Pancreas
Intervention: Drug: propofol
Sponsors: King Chulalongkorn Memorial Hospital; King Chulalongkorn Memorial Hospital
Completed - verified February 2012 - Condition: Type 1 Diabetes
Interventions: Drug: Pro insulin peptide; Drug: Pro insulin peptide; Drug: Saline
Sponsors: Cardiff University; Cardiff University; Diabetes Vaccine Development Centre; Juvenile Diabetes Research Foundation
Recruiting - verified April 2012 - Condition: Healthy Individuals
Interventions: Drug: d-Cycloserine; Drug: Lactose pill; Genetic: Saliva sample; Other: Functional neuroimaging (fMRI)
Sponsors: Universitaire Ziekenhuizen Leuven; Universitaire Ziekenhuizen Leuven
Not yet recruiting - verified December 2011 - Condition: Type 2 Diabetes
Intervention:
Sponsors: Diabetes Care Center; Diabetes Care Center; Medtronic
Recruiting - verified March 2012 - Condition: Status Asthmaticus
Interventions: Drug: budesonide, albuterol, IB; Drug: Normal saline, albuterol, ipratropium bromide
Sponsors: King Saud University; King Saud University; King Fahad Medical City
Recruiting - verified February 2012 - Condition: Diabetic Macular Edema
Interventions: Drug: dexamethasone - Cyclodextrin eye drops; Other: intravitreal Avastin injection +/- macular laser
Sponsors: King Saud University; King Saud University
Not yet recruiting - verified January 2012 - Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide/Low dose Dex; Drug: Bortezomib/Lenalidomide/ Low dose Dex; Drug: Lenalidomide
Sponsors: King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center
Recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Drug: Standard cyclophosphamide; Drug: Goserelin (Zoladex)
Sponsors: King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center
Active, not recruiting - verified February 2012 - Condition: Acquired Aplastic Anaemia
Intervention: Drug: Rabbit ATG, Thymoglobuline (Genzyme)
Sponsors: King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center
Active, not recruiting - verified February 2012 - Conditions: Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS)
Intervention: Drug: CPI-613
Sponsors: Cornerstone Pharmaceuticals, Inc.; Cornerstone Pharmaceuticals, Inc.
Not yet recruiting - verified February 2012 - Conditions: Placebo Effect; Drug Half Life; Pharmacokinetics
Interventions: Drug: Caffeine, paracetamol, cephalexin, or ibuprofen; Drug: Placebo (caffeine, paracetamol, cephalexin, or ibuprofen)
Sponsors: King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center
Not yet recruiting - verified December 2011 - Conditions: Placebo Effect; Placebo Drug Interaction
Interventions: Drug: Hydroxizine; Other: Placebo; Drug: hydroxyzine/placebo
Sponsors: King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center
Recruiting - verified December 2011 - Condition: Acne Vulgaris
Interventions: Drug: adapalene 0.1% and benzoyl peroxide 2.5% topical gel; Drug: EPIDUO; Drug: Placebo (Vehicle Gel)
Sponsors: Actavis Mid-Atlantic LLC; Actavis Mid-Atlantic LLC
Completed - verified December 2011 - Conditions: Head and Neck Cancer; Kidney Cancer; Liver Cancer; Sarcoma
Interventions: Drug: sorafenib tosylate; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Other: enzyme-linked immunosorbent assay; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Malignant Salivary Gland Tumors
Interventions: Drug: Cisplatin: 40 mg/m2 weekly during radiation; Radiation: Radiation: 60-66 Gy in 2 Gy daily fractions
Sponsors: King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center; Radiation Therapy Oncology Group
Recruiting - verified December 2011 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Ranolazine; Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2012 - Condition: Cancer
Intervention:
Sponsors: King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center
Not yet recruiting - verified January 2012 - Condition: Dyslipidemia
Interventions: Drug: levothyroxine; Drug: sugar pill
Sponsors: King Saud University; King Saud University
Recruiting - verified December 2011 - Conditions: Acetaminophen Overdose; Pain
Intervention: Behavioral: Active Ingredient Icon
Sponsors: Northwestern University; Northwestern University; Emory University; McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Not yet recruiting - verified May 2012 - Condition: Premenstrual Syndrome
Interventions: Drug: EE 20 microgram with desogestrel 150 mg; Drug: EE 20 microgram with drospirenone 3 mg
Sponsors: Chulalongkorn University; Chulalongkorn University
Completed - verified March 2012 - Condition: Rheumatoid Arthritis
Intervention: Biological: Adalimumab
Sponsors: Abbott; Abbott
Recruiting - verified April 2012 - Condition: Insomniac Postmenopausal Women
Interventions: Drug: Estrogen patch; Drug: Placebo
Sponsors: Chulalongkorn University; Chulalongkorn University
Recruiting - verified December 2011 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Ranolazine; Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2012 - Condition: Overactive Bladder
Interventions: Drug: Tarafenacin 0.2 mg; Drug: Placebo; Drug: Tarafenacin 0.4 mg
Sponsors: Kwang Dong Pharmaceutical co., ltd.; Kwang Dong Pharmaceutical co., ltd.
Recruiting - verified October 2011 - Conditions: Alzheimer's Disease; Schizophrenia
Interventions: Drug: amisulpride; Drug: amisulpride; Drug: amisulpride
Sponsors: Institute of Psychiatry, London; Institute of Psychiatry, London
Not yet recruiting - verified October 2011 - Condition: Laryngospasm
Interventions: Drug: Lidocaine; Other: Placebo
Sponsors: King Saud University; King Saud University; Albany College of Pharmacy and Health Sciences
Recruiting - verified April 2012 - Conditions: Cerebral Palsy; Post-operative Pain
Intervention: Drug: botulinum toxin intramuscular injection
Sponsors: Guy's and St Thomas' NHS Foundation Trust; Guy's and St Thomas' NHS Foundation Trust
Recruiting - verified March 2012 - Condition: Type 1 Diabetes Mellitus
Interventions: Other: Closed-loop; Other: Conventional insulin pump delivery
Sponsors: University of Cambridge; University of Cambridge; Diabetes UK
Not yet recruiting - verified September 2011 - Conditions: Diabetes; Foot Ulcers; Infection
Intervention: Drug: antibiotics
Sponsors: King's College Hospital NHS Trust; King's College Hospital NHS Trust
Not yet recruiting - verified January 2011 - Condition: HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL)
Intervention: Drug: CHOP-daclizumab
Sponsors: King's College Hospital NHS Trust; King's College Hospital NHS Trust
Completed - verified July 2011 - Condition: Sickle Cell Anemia
Intervention: Drug: Hydroxyurea
Sponsors: Baylor College of Medicine; Baylor College of Medicine; National Heart, Lung, and Blood Institute (NHLBI); Children's Hospital Boston; Children's Hospital Medical Center, Cincinnati; University of Texas Southwestern Medical Center; Children's Healthcare of Atlanta; Children's Hospital of Philadelphia; The Hospital for Sick Children; Children's Research Institute; Columbia University; St. Jude Children's Research Hospital; Virginia Commonwealth University; Rainbow Babies Hospital; University of South Alabama; Medical University of South Carolina; Cohen Children's Medical Center; University of Alabama at Birmingham; University of Miami; University of Mississippi Medical Center; Wayne State University; Children's Hospital of The King's Daughters; Nemours Children's Clinic; Duke University; East Carolina University; Children's Hospitals and Clinics of Minnesota; Children's Memorial Hospital
Recruiting - verified March 2012 - Conditions: Cognitive/Functional Effects; Leukemia; Neurotoxicity; Pain; Therapy-related Toxicity
Interventions: Drug: clofarabine; Drug: cyclophosphamide; Drug: cytarabine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: hydrocortisone sodium succinate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: thioguanine; Drug: vincristine sulfate; Radiation: selective external radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Coronary Artery Disease; Atherosclerosis; Acute Coronary Syndrome (ACS); Myocardial Infarction (MI)
Intervention: Device: PTCA with stent placement
Sponsors: OrbusNeich; OrbusNeich; Genae associates
Recruiting - verified January 2012 - Condition: Cocaine Dependence
Interventions: Drug: Buprenorphine + Naltrexone; Drug: Placebo + Naltrexone
Sponsors: University of California, Los Angeles; Walter Ling; National Institute on Drug Abuse (NIDA); The EMMES Corporation
Recruiting - verified February 2012 - Condition: HIV Infected
Intervention: Drug: Tenofovir, Emtricitabine, Atazanavir, Ritonavir
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012 - Condition: Labor Pain
Interventions: Drug: Acetaminophen; Drug: Meperidine
Sponsors: King Abdulaziz University; King Abdulaziz University; King Abdulaziz Medical City
Completed - verified July 2011 - Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome; Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma
Intervention: Drug: BMN 673
Sponsors: BioMarin Pharmaceutical; BioMarin Pharmaceutical
Recruiting - verified March 2012 - Condition: Cardiac Arrest
Interventions: Drug: amiodarone; Drug: Lidocaine; Other: Normal saline
Sponsors: University of Washington; University of Washington; National Heart, Lung, and Blood Institute (NHLBI); Canadian Institutes of Health Research (CIHR); Heart and Stroke Foundation of Canada; American Heart Association; Defence Research and Development Canada; U.S. Army Medical Research and Materiel Command
Not yet recruiting - verified February 2012 - Conditions: Sickle Cell Disease; Stroke
Interventions: Drug: Hydroxyurea; Drug: Placebo
Sponsors: Johns Hopkins University; Johns Hopkins University; National Center for Research Resources (NCRR); Washington University School of Medicine; Vanderbilt University School of Medicine; University of Alabama at Birmingham; Children's Hospital of Philadelphia; Children's Hospital Medical Center, Cincinnati; Medical University of South Carolina; RTI International
Recruiting - verified March 2012 - Condition: Leukemia
Interventions: Drug: asparaginase; Drug: bortezomib; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: mitoxantrone hydrochloride; Drug: sorafenib tosylate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Intervention: Drug: Insulin detemir
Sponsors: Diabetes Care Center; Diabetes Care Center
Completed - verified February 2012 - Conditions: Bacterial Infection; Leukemia; Musculoskeletal Complications; Neutropenia
Interventions: Drug: levofloxacin; Procedure: standard follow-up care
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: HIV; Impaired Cognition
Interventions: Drug: standard care; Drug: novel treatment
Sponsors: Imperial College London; Imperial College London; Pfizer
Not yet recruiting - verified June 2011 - Condition: Glioblastoma
Intervention: Drug: TMZ
Sponsors: King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center
Completed - verified April 2012


